Helen M. Thackray - 31 Mar 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Chief R&D Officer
Issuer ticker: BCRX
Reported as of: 31 Mar 2025
Net transaction value: -$56,438
SEC form: 4
Accepted by SEC: 02 Apr 2025, 16:18:50 UTC
Prior SEC filing: 23 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Helen M. Thackray filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 02 Apr 2025.

Key facts

This page summarizes Helen M. Thackray's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Apr 2025, 16:18.

Change

Previous filing in this sequence was filed on 23 Dec 2024.
Current net transaction value: -$56,438.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Tax liability

Transaction value: $56,438
Shares: -7,525
Change %: -2%
Price: $7.50
Shares after: 377,318
Date: 31 Mar 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.